Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Merus NV (MRUS)

NASDAQ
Currency in USD
Disclaimer
52.09
-0.89(-1.68%)
Closed
Pre Market
51.50-0.59(-1.13%)
MRUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
51.7453.02
52 wk Range
19.8161.61
Prev. Close
52.09
Open
53.01
Day's Range
51.74-53.02
52 wk Range
19.81-61.61
Volume
718,383
Average Volume (3m)
568,514
1-Year Change
145.71%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
MRUS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
88.08
Upside
+69.09%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

InvestingPro Research for Merus NV


Bispecific Breakthrough
Merus N.V. leads in developing innovative bispecific antibody therapeutics, targeting multiple cancer pathways simultaneously with promising results.
Zenocutuzumab's Potential
Explore the broad efficacy of Merus's lead candidate across various tumor types, with potential BLA filings for lung and pancreatic cancers in 2024.
Diverse Pipeline Progress
Delve into Merus's robust pipeline, including MCLA-145, MCLA-129, and petosemtamab, showcasing encouraging efficacy in clinical trials across multiple cancers.
Market Outlook
Analysts project revenue growth from $44M in 2023 to $112M in 2025, with a $58 price target, reflecting Merus's potential in the expanding oncology market.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Compare MRUS to Peers and Sector

Metrics to compare
MRUS
Peers
Sector
Relationship
P/E Ratio
−21.2x−3.0x−0.6x
PEG Ratio
−0.870.000.00
Price/Book
4.8x2.7x2.6x
Price / LTM Sales
101.0x8.7x3.3x
Upside (Analyst Target)
68.9%254.2%49.0%
Fair Value Upside
Unlock23.3%7.7%Unlock

FAQ

What Is the Merus (MRUS) Stock Price Today?

The Merus stock price today is 52.09.

What Stock Exchange Does Merus Trade On?

Merus is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Merus?

The stock symbol for Merus is "MRUS."

What Is the Merus Market Cap?

As of today, Merus market cap is 3.57B.

What is Merus Earnings Per Share?

The Merus EPS is -2.89.

What Is the Next Merus Earnings Date?

Merus will release its next earnings report on 29 Oct 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.